These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37180666)

  • 21. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
    Wang X; Jing H; Li H
    Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anoikis Patterns in Cervical Cancer: Identification of Subgroups and Construction of a Novel Risk Model for Predicting Prognosis and Immune Response.
    Xiang X; Ding J
    Front Biosci (Landmark Ed); 2023 Nov; 28(11):287. PubMed ID: 38062824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
    Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
    Front Genet; 2022; 13():975905. PubMed ID: 36313456
    [No Abstract]   [Full Text] [Related]  

  • 24. Identification and Validation of Anoikis-Related Signatures for Predicting Prognosis in Lung Adenocarcinoma with Machine Learning.
    Wang Q; Sun N; Zhang M
    Int J Gen Med; 2023; 16():1833-1844. PubMed ID: 37213475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel lactate metabolism-related signature predicts prognosis and tumor immune microenvironment of breast cancer.
    Zhang Z; Fang T; Lv Y
    Front Genet; 2022; 13():934830. PubMed ID: 36171887
    [No Abstract]   [Full Text] [Related]  

  • 26. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
    Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
    Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
    Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
    Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and verification of eight cancer-associated fibroblasts related genes as a prognostic signature for head and neck squamous cell carcinoma.
    Dong L; Sun Q; Song F; Song X; Lu C; Li Y; Song X
    Heliyon; 2023 Mar; 9(3):e14003. PubMed ID: 36938461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of a ferroptosis-related gene signature for prognosis in lung adenocarcinoma patients.
    Cai J; Li C; Li H; Wang X; Zhou Y
    PeerJ; 2021; 9():e11931. PubMed ID: 34434660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction and validation of a prognostic model based on stage-associated signature genes of head and neck squamous cell carcinoma: a bioinformatics study.
    Chen L; Zhang X; Lin J; Wen Y; Chen Y; Chen CB
    Ann Transl Med; 2022 Dec; 10(24):1316. PubMed ID: 36660709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma.
    Yue C; Ma H; Zhou Y
    PeerJ; 2019; 7():e8128. PubMed ID: 31803536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and validation of a novel prognostic model of inflammation-related gene signature of lung adenocarcinoma.
    Luo D; Feng W; Ma Y; Jiang Z
    Sci Rep; 2022 Aug; 12(1):14729. PubMed ID: 36042374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Set of Immune-associated Gene Signature predicts Biochemical Recurrence in Localized Prostate Cancer Patients after Radical Prostatectomy.
    Luan JC; Zhang QJ; Zhao K; Zhou X; Yao LY; Zhang TT; Zeng TY; Xia JD; Song NH
    J Cancer; 2021; 12(12):3715-3725. PubMed ID: 33995646
    [No Abstract]   [Full Text] [Related]  

  • 34. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Risk-Assessing Signature Based on Hypoxia- and Immune-Related Genes for Prognosis of Lung Adenocarcinoma Patients.
    Wang Y; Feng J; Liu Y; Han T
    Comput Math Methods Med; 2022; 2022():7165851. PubMed ID: 36213576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
    Huang D; Tang E; Zhang T; Xu G
    Front Immunol; 2022; 13():916284. PubMed ID: 35860256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An
    Han Y; Wong FC; Wang D; Kahlert C
    Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction and validation of a novel prognostic signature of microRNAs in lung adenocarcinoma.
    Li W; Liu S; Su S; Chen Y; Sun G
    PeerJ; 2021; 9():e10470. PubMed ID: 33510968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
    Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
    Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.